Drugs used to treat various disorders target GABA A receptors. To develop R subunit selective compounds, we synthesized 5-(4-piperidyl)-3-isoxazolol (4-PIOL) derivatives. The 3-isoxazolol moiety was substituted by 1,3,5-oxadiazol-2-one, 1,3,5-oxadiazol-2-thione, and substituted 1,2,4-triazol-3-ol heterocycles with modifications to the basic piperidine substituent as well as substituents without basic nitrogen. Compounds were screened by [ 3 H]muscimol binding and in patch-clamp experiments with heterologously expressed GABA A R i 3 γ 2 receptors (i ) 1-6). The effects of 5-aminomethyl-3H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all R subunit isoforms. 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at R 2 -, R 3 -, and R 5 -containing receptors. When coapplied with GABA, they were antagonistic in R 2 -, R 4 -, and R 6 -containing receptors and potentiated R 3 -containing receptors. 6a protected GABA binding site cysteine-substitution mutants R 1 F64C and R 1 S68C from reacting with methanethiosulfonate-ethylsulfonate. 6a specifically covalently modified the R 1 R66C thiol, in the GABA binding site, through its oxadiazolethione sulfur. These results demonstrate the feasibility of synthesizing R subtype selective GABA mimetic drugs.
Introduction

γ-Aminobutyric acid type A receptors (GABA A
) are responsible for most of the fast inhibitory synaptic transmission in mammalian brain. They belong to the Cys-loop receptor superfamily of ligand-gated ion channels. These receptors are formed by the pentameric assembly of homologous subunits and contain an anion-selective transmembrane channel. Numerous GABA A receptor subunits have been identified (R 1-6 , 1-3 , γ 1-3 , δ, π, ε, and θ), all of which are products of separate genes. [1] [2] [3] Most GABA A receptors contain two R, two and either a γ or a δ subunit. Recombinant GABA A receptors with different subunit isoform composition display differing sensitivity to the endogenous agonist GABA. 4 The GABA A receptor subunits exhibit distinct, although overlapping, regional distribution patterns within the brain, with expression patterns changing during pre-to postnatal development. 5 In addition, in neurons expressing multiple receptor isoforms, subunit-selective targeting to distinct cellular domains has been observed. 6, 7 The subunit isoform diversity and brain region specific expression patterns form the basis for the functional and pharmacological heterogeneity of GABAergic neurotransmission. Presently, most drug therapy for anxiety, epilepsy, and surgical sedation and often for insomnia targets GABA A receptor subtypes nonselectively, but the heterogeneity of the receptors theoretically holds the promise for brain region-or even cell-selective pharmacological intervention, which would increase the specificity of the effects and decrease the incidence of undesirable side effects.
Most of the known pharmacological heterogeneity of GABA A receptors concerns the sensitivity of the benzodiazepine site that is formed at the interface between the R and γ subunits. [8] [9] [10] Receptors lacking the γ 2 subunit or containing the R 4 or R 6 subunits are practically insensitive to benzodiazepine site agonists. [11] [12] [13] [14] The two GABA binding sites are formed at the interfaces between the and R subunits. Only a few different structural classes of ligands are known for the GABA binding site, reflecting the strict structural requirements for GABA A receptor recognition and activation. To date, these GABA binding site agonist compounds display little subunit subtype specificity with gaboxadol forming a class on its own as a "superagonistic" GABA mimetic. 15 A few compounds have been identified that neither bind to the benzodiazepine nor the GABA binding sites and yet still show subtype-selective antagonistic activity, these include furosemide, otherwise known as a Na
-cotransporter blocker, that selectively blocks R( 4/6 ) ( 2/3 )γ 2 receptors, 16, 17 and clozapine, an atypical antipsychotic drug that inhibits furosemide-insensitive R 1 containing receptors. 18 Undesirable side effects, such as sedation and amnesia, often limit the clinical use of benzodiazepines 19 as well as the use of full agonists and of zero modulators of the GABA recognition site. 20 Different strategies exist to minimize undesirable effects: subtype-selective ligands or partial agonists. Studies with transgenic rodents have helped to dissect the R-subunit isoforms involved in specific pharmacologic effect of benzodiazepines. For example, R 2 -containing receptors are primarily responsible for anxiolytic effects of benzodiazepines whereas R 1 -containing receptors are more important for the sedative side effects.
Current research efforts focus on designing subunit-selective benzodiazepines. [21] [22] [23] [24] [25] [26] [27] In general, it seems desirable to have subtype-selective ligands that only act on a certain receptor subtype that is involved in transducing the desired effect and not on other subtypes that are involved in undesired effects. A complementary approach is to develop partial agonists of the GABA recognition site that induce only submaximal activation of specific R-subunit containing receptors. Under close to complete receptor occupancy, these partial agonists act as inhibitors of full agonists. 15 Partial agonists at the benzodiazepine site have also been investigated. [28] [29] [30] In a previous study, we used binding studies on rat brain cryostat sections and patch-clamp experiments with heterologously expressed recombinant GABA A receptors to characterize the low-efficacy GABA mimetic 5-(4-piperidyl)isoxazol-3-ol (4-PIOL) ( Figure 1 ) as a weak partial agonist or antagonist depending on the brain area and the GABA A receptor composition. 31, 32 Therefore, we synthesized and functionally characterized different 5-(4-piperidyl)-1,3,4-oxadiazol-and 5-(4-piperidyl)-1,3,4-triazol-derivatives compounds structurally related to 4-PIOL. 33 The effects of other 4-PIOL derivatives on GABA A receptors have been studied previously. [34] [35] [36] [37] [38] [39] [40] All compounds were screened for efficacy and potency to GABA A receptors in native membranes using a [ 3 H]muscimol binding assay. Substances inducing changes in [ 3 H]muscimol binding in the micromolar concentration range were further analyzed in patch clamp recordings from GABA A receptors heterologously expressed in human embryonic kidney (HEK 293) cells. The R subunit specificity of these compounds was tested in R i 3 γ 2 (i ) 1-6) GABA A receptors by measuring the modulation of GABA-induced chloride current and the intrinsic activity of the compounds. We also sought to demonstrate that the actions of these new compounds were mediated through binding at the GABA-binding sites. We used a variant of the substituted cysteine accessibility method (SCAM) in order to identify the position and orientation of 6a in the binding site. 41 Residues in the R subunit that line the GABA binding site have been identified based on the effects of mutations on electrophysiological properties, [42] [43] [44] photoaffinity labeling, 45 and SCAM. [46] [47] [48] They include those aligned with rat R 1 positions F64, R66, S68, and T129. Although crystal structures of GABA A receptor binding sites are not yet available, homology models based on the snail acetylcholine binding protein (AChBP) structure provide a reasonable molecular context in which to interpret our results. 49 
Synthesis
The synthetic procedures for the 5-(4-piperidyl)-1,3,4-oxadiazole-and 5-(4-piperidyl)-1,3,4-triazole-derivatives in this study are depicted in Schemes 1 and 2, whereas Schemes 3 and 4 depict specific variations of the 4-piperidyl moiety. Here we describe the synthesis of the 4-piperidyl-derivatives as an example. The secondary amine function of 4-piperidine-carboxylic acid ester was either protected with the t-butoxycarbonyl (Boc) group using di-t-butyldicarbonate and NaHCO 3 in water or triethylamine in methylene chloride (Scheme 1: 1a) or alkylated using formaldehyde, formic acid, or benzylchloride (Scheme 2: 7a,b). Subsequently, the esters were converted to the corresponding acid hydrazides (Scheme 1: 2a; Scheme 2: 8a,b) by refluxing the ester in an excess of hydrazine hydrate. The 1,3,4-oxadiazol-2-ones (Scheme 1: 3a; Scheme 2: 9a,b) were prepared by refluxing the hydrazides with N,N′-carbonyldiimidazol (CDI) in the presence of triethylamine in a mixture of THF and DMF. The corresponding 1,3,4-oxadiazol-2-thiones (Scheme 1: 4a; Scheme 2: 10a,b) were synthesized by refluxing the hydrazides with carbonyldisulfide in an ethanolic potassium hydroxide solution. Theoretically, oxadiazol-2-ones and -thiones can exist in two tautomeric forms, the amide form and the imino- alcohol form. IR, UV, and NMR spectra, however, indicate that they exist predominantly in their amide-form. 50 The hydrazide 2a was also cyclized with triethoxyethane to yield the 2-methyl-1,3,4-oxadiazol-derivative (Scheme 1: 18). Reaction of the hydrazide 2a with benzylisocyanate or benzylisothiocyanate produced the acylated semicarbazide derivatives 12a and 13a, which were converted to benzyl-1,3,4-oxadiazoles 14 and 15 by refluxing with NaOH in an aqueous solution (Scheme 1). N-methyl-piperidin-4-yl carboxylic acid hydrazide (8b) was reacted with triethoxymethane to yield the 2-unsubstituted 1,3,4-oxadiazol-derivative 11 (Scheme 2). The 4-piperidyl moiety was varied as outlined in Scheme 3 and 4. It was substituted by a 3-piperidyl and a 2-pyrrolidinyl moiety, or residues that lead to derivatives that mimic glycine, sarcosine, alanine, and -alanine (Scheme 3) as well as N-alkylated 4-piperidinylcompounds, dimethylglycine, and two compounds without an amine function (Scheme 4). The last step during the synthesis of compounds 5a-g, 6a-e,g, 16a, 17a, and 19 was the removal of the Boc-protective group with hydrogen chloride (Scheme 1 and 3). (Table 1) , to enable us to detect pronounced differences in subtype selectivity of the compounds.
Pharmacology
Of the 28 compounds tested, six fulfilled our criteria for full binding analysis in that, at 100 µM, they inhibited muscimol binding by at least 30% (Table 1) . These six included 5a, 5d, 5g, 6a, 6d, and 19. For these compounds, we determined the IC 50 Figure 2 ). 5d showed the highest affinity with an IC 50 of 1.4 µM, and 5a exhibited the lowest affinity, 183 µM ( Table 2) . None of the six compounds displayed significant differences between IC 50 determined in cortical vs cerebellar membranes, although compound 5g showed a significant difference between the pseudo-Hill coefficient determined in cortical vs cerebellar membranes, 0.63 vs 0.92, respectively, whereas no difference in any measure was detected for the other compounds (Table 2) .
HEK293 Electrophysiology. We characterized the functional effects of four compounds on R i 3 γ 2 (i ) 1-6) GABA A receptors using patch-clamp experiments with heterologously expressed GABA A receptors. This allowed us to determine directly the GABA A receptor R subunit specificity for these four compounds identified as the most potent inhibitors in the [ 3 H]muscimol binding assays described above. Transiently transfected HEK 293 cells coexpressing an R variant plus 3 and γ 2 S and enhanced green fluorescent protein (EGFP) were used in these experiments. EGFP fluorescence facilitated the identification of transfected cells for patch clamping. For each compound, we applied a series of increasing drug concentrations either alone, to assess the intrinsic agonist activity, or together with the approximate EC 20 to EC 25 concentration of GABA, to determine its GABA-modifying activity. The GABA EC [20] [21] [22] [23] [24] [25] concentrations used for the different R subunits are shown in Table 3 .
Intrinsic Agonist Activity (5a). (5-Piperidin-4-yl-3H- [1, 3, 4] oxadiazol-2-one hydrochloride) and 6a (5-piperidin-4-yl-3H- [1, 3, 4] oxadiazol-2-thione hydrochloride) showed limited intrinsic activity in R 1 , R 4 , and R 6 containing receptors ( Figure  3 ). At 1 mM, the induced currents were less than 10% of the currents induced by the approximate EC 100 GABA concentrations ( Figure 4 ). In contrast, on R 2 , R 3 , and R 5 containing receptors, 1 mM 5a caused currents of 17 ( 1%, 18 ( 2%, and 34 ( 3% of the maximal GABA-induced currents. On the same receptors, 1 mM 6a induced currents that were 23 ( 5%, 13 ( 2%, and 48 ( 4% of the maximal GABA-induced currents.
5d (5-aminomethyl-3H- [1, 3, 4] oxadiazol-2-one hydrochloride) induced desensitizing currents in all GABA A receptor combinations tested in a dose-dependent manner with an efficacy >50% of the maximal GABA-induced currents and an R subunit specific potency (Table 4, Figure 3 ). Receptors containing R 6 subunits were most sensitive, with an EC 50 of 30 µM and receptors containing the R 3 subunit were the least sensitive with a 5d EC 50 of ca. 2300 µM.
The ability of 19 (4-(5-methyl-[1,3,4]oxadiazol-2-yl)-piperidine hydrochloride) to directly activate GABA A receptors was restricted to R 6 containing receptors, where it induced currents 3 H]muscimol binding to cortical (squares) and cerebellar (circles) membranes. Binding data were normalized to the binding in the absence of any inhibitor set to 100%. Error bars indicate the SEM for at least three independent tissue preparations.
29 ( 4% of the maximal GABA-evoked currents. With all of the other R subunits 1 mM 19 induced a current less than 10% of the maximal GABA-induced current.
GABA Modulatory Effect. 5a showed a slight dosedependent potentiating effect on R 3 and R 5 containing GABA A receptors with maximal current potentiation by 1 mM 5a of 22 ( 11% for R 3 and 34 ( 5% for R 5 containing receptors ( Figure  4 ). In all other R subunits, its action was antagonistic on GABAinduced currents with similar potency. Its antagonistic efficacy was highest in R 1 containing receptors, where 1 mM 5a inhibited GABA-induced current by 77 ( 3%. At this concentration, 5a inhibited GABA-induced currents of other R subunits by 42 ( 2% for R 2 , 52 ( 5% for R 4 , and 41 ( 4% for R 6 .
6a (5-piperidin-4-yl-3H- [1, 3, 4] oxadiazol-2-thione hydrochloride), the thioderivative of 5a, had similar effects to 5a except on R 2 containing receptors. 6a potentiated GABA-induced currents in R 5 3 γ 2 receptors to an extent similar to that described for 5a, but on R 3 3 γ 2 receptors, the potentiating effect of 6a was higher with a current potentiation of 114 ( 8% at 1 mM. In contrast to 5a, in R 2 -containing receptors, low concentrations of 6a potentiated submaximal GABA-induced currents with maximal potentiation of 39 ( 4% at 1 µM, whereas at 1 mM, 6a inhibited GABA currents by 24 ( 9%. 6a also inhibited GABA-induced currents in R 1 , R 4 , and R 6 containing receptors.
5d (5-aminomethyl-3H- [1, 3, 4] oxadiazol-2-one hydrochloride) potentiated the GABA-induced currents for all of the R subunit isoforms with similar potency, apparent EC 50 values ranged between 100 and 300 µM (Figure 3) . The efficacy was similar in R 1 , R 2 , R 3 , and R 4 containing receptors with current potentiation of 302 ( 35%, 324 ( 40%, 311 ( 18%, and 334 ( 13% at 1 mM, respectively. The 5d efficacy was significantly enhanced in receptors comprising R 5 (423 ( 25%) and R 6 (437 ( 21%) subunits with p of <0.01 in a two-sided t test compared to R 1 containing receptors.
Lastly, we analyzed the GABA A receptor R subunit specificity of 19 (4-(5-methyl- [1, 3, 4] oxadiazol-2-yl)-piperidine hydrochloride) and its hydrobromide with electrophysiological methods. This novel compound increased the GABA-induced currents in all GABA A receptor combinations tested with similar potency. The efficacy shows a slight subtype specificity that could be divided into two significantly different groups with p of <0.01 in a two-sided t test. The group with higher efficacy consisting of R 2 , R 4 , R 5 , and R 6 with positive modulation of the GABAinduced currents ranging from 48% in R 2 to 87% in R 6 at 1 mM 19. The positive modulation efficacy was smaller for R 3 and R 1 containing receptors, where compound 19 potentiated the GABA-induced currents by 11% ( 2 and by 21% ( 5, respectively.
Two-Electrode Voltage Clamp Electrophysiology in
Xenopus laeWis Oocytes
On the basis of the diverse set of effects, potentiation, inhibition, and direct activation seen with the compounds, we sought to demonstrate that they bound in the GABA binding site. These experiments focused on compound 6a. We used a series of cysteine-substitution mutants in the GABA binding site.
Determination of GABA EC 50 Values. GABA dose-response relationships were determined for wild type and mutant R 1 2 receptors expressed in Xenopus oocytes (Table 5 ). Mutant R 1 S68C 2 receptors had an EC 50 value comparable to R 1 2 wt receptors. In contrast, the EC 50 values for the mutants R 1 T129C 2 , R 1 F64C 2 , and R 1 R66C 2 were increased 14-fold, 43-fold, and 554-fold, respectively, compared to wild type, in agreement with previously published data. 46, 47 Determination of 6a EC 50 . 6a acted as an agonist on R 1 2 wt, R 1 F64C 2 , and R 1 S68C 2 receptors. To prove that the 6a-induced currents were mediated by GABA A receptor activation, we tested the ability of picrotoxinin, an open channel blocker, to inhibit the 6a induced currents. Coapplication of 100 µM picrotoxinin and 10 mM 6a inhibited 6a-induced currents by 80-90% ( Figure 5 ). We infer that 6a directly activates GABA A receptors.
We determined the 6a EC 50 for the Cys-substitution mutant receptors (Table 5) . For wt receptors, the 6a EC 50 was 9.5 mM. It was similar for R 1 S68C 2 . For R 1 F64C 2 , the 6a EC 50 was 0.6 fold less than for wt.
The efficacy of 6a as compared to GABA was significantly greater for R 1 F64C 2 receptors compared to R 1 2 wt and R 1 S68C 2 . A 30 mM concentration of 6a produced currents that were 60, 20, and 17% as large as the maximal GABA current for R 1 F64C 2 , R 1 2 wt, and R 1 S68C 2 receptors, respectively. Higher concentrations of 6a were not used due to the limited supply of the compound. The Hill coefficient of the 6a dose-response relationship was increased compared to GABA.
Determination of 6a IC 50 Values of the Mutants. Coapplication of 6a and GABA inhibited the GABA-induced currents. We performed competition experiments to determine the 6a IC 50 for inhibiting GABA EC 20 currents with R 1 2 wt, R 1 F64C 2 , and R 1 S68C 2 receptors (Table 5 ). One mM 6a inhibited the EC 20 GABA current by more than 90% in these receptors. The residual GABA currents observed during the coapplication of 1 mM 6a and GABA EC 20 concentration, were 6.8 ( 1.0% (n ) 4) for R 1 2 wt, 9.0 ( 2.0% (n ) 3) for R 1 F64C 2 , and 3.0 ( 1.8% (n ) 6) for R 1 S68C 2 . Because the 6a-GABA competition experiments were done at a relatively low GABA concentration, we decided that for the protection experiments the 6a concentration should be at least 1 mM.
Effects of MTS-Reagents on the Cysteine Mutants and Reaction Rates. Methanethiosulfonate (MTS) reagents react 10 9 times faster with ionized thiolates (S -) than with thiols (SH); 51 thus, they are much more likely to react with water-accessible cysteine, which can ionize. We monitored the MTS reaction with a substituted cysteine by its effect on the channel's macroscopic currents. Application of the anionic reagent MTS-ethylsulfonate (MT-SES -) did not affect the GABA current in R 1 2 wt receptors (data not shown). 46 After complete reaction with MTSES -and/ or MTSEA-biotin, subsequent GABA EC 50 currents were inhibited to a similar extent for R 1 F64C 2 , R 1 R66C 2 , R 1 S68C 2 , and R 1 T129C 2 receptors (see Table 6 ). We infer that in the cysteine-substitution mutants, changes in the GABAinduced current after MTS application were due to the covalent modification of the engineered cysteine. Figure 6 ). 46 For R 1 R66C 2 and R 1 T129C 2 , the second-order reaction rate constant for MTSEA-biotin with R 1 R66C 2 was 5500 ( 1600 M -1 /s and with R 1 T129C 2 was 6700000 ( 1100000 M -1 /s (Table 6 ). All reaction rates were well fit by a monoexponential function. For each mutant receptor, however, there are two engineered cysteine residues because R -receptors are pentameric and their subunit stoichiometry is proposed to be 2R:3 . 52, 53 Either the two cysteine residues from each receptor reacted at the same rate, or reaction at only one residue gave the complete effect. These two possibilities are indistinguishable with the present methods. tion may be due either to direct steric protection due to the presence of GABA in the binding site or to a GABA-induced conformational change reducing the accessibility of these residues to the MTS reagent. The fact that these cysteine mutants were also protected from modification by SR-95531, a competitive antagonist, implies that the mechanism of protection is a steric not an allosteric one. The first trace shows a 6a induced current. The second trace was recorded during a 20 s application of picrotoxinin, immediately followed by a coapplication of 6a and picrotoxinin. 
for GABA EC50 currents after complete reaction with MTSES -and MTSEA-biotin on GABAA receptors containing the cited cys-engineered R 1 subunit together with the 2 subunit expressed in Xenopus oocytes. n.d. ) not determined.
8).
In control experiments with R 1 F64C 2 , a 12 s application of 10 µM MTSES -caused an 87 ( 3% (n ) 4) reduction in subsequent GABA EC 50 test currents ( Figure 7A ). In contrast, a 12 s coapplication of 10 µM MTSES -with 3.6 mM GABA caused only a 35 ( 1% (n ) 5) reduction of the subsequent GABA-induced currents ( Figure 7B ) and coapplication of 10 µM MTSES -with 10 mM 6a resulted in only a 47 ( 6% (n ) 4) reduction ( Figure 7C ) of the subsequent GABA-induced currents. Thus, the extent to which MTSES -could react with R 1 F64C 2 was reduced by the presence of GABA and 6a. This implies that both agonists protected the engineered cysteine from covalent modification.
Similarly, for the R 1 S68C 2 mutant, application of 450 µM MTSES -for 12 s reduced the subsequent GABA test currents by 77 ( 5% (n ) 4) ( Figure 8 ). Coapplication of 450 µM MTSES -with 65 µM GABA or 10 mM 6a only reduced the subsequent GABA test currents by 40 ( 2% (n ) 4) and 10 ( 4% (n ) 4), respectively, consistent with protection of the R 1 S68C cysteine residue.
In similar experiments with R 1 R66C 2 receptors, 10 mM 6a demonstrated slight, but significant protection of the engineered cysteine from reaction with MTSES - (Figure 8 ). A 12 s application of 2 mM MTSES -to R 1 R66C 2 inhibited 91 ( 3% (n ) 6) of the subsequent GABA EC 50 current. Coapplication of 35 mM GABA with MTSES -inhibited 49 ( 6% (n ) 3) of the subsequent test currents, consistent with protection by GABA. In contrast, application of 10 mM 6a with 2 mM MTSES -resulted in 77 ( 4% (n ) 5) inhibition of the subsequent GABA test currents. Comparable results were obtained for MTSEA-biotin, application of 30 mM 6a with MTSEA-biotin resulted in 79 and 87% (n ) 2) inhibition of the subsequent GABA test currents as compared to 87 and 100% (n ) 2) inhibition in control experiments. For R 1 R66C, the results of the protection experiments are complicated by the fact that 6a reacts with R 1 R66C 2 as described below.
6a Reacts with the Engineered Cysteine in r 1 R66C 2 Receptors. To our surprise, while examining competition between GABA and 6a on R 1 R66C 2 receptors, we noted that once the oocytes showed stable GABA test responses, coapplication of GABA and 6a irreversibly reduced the subsequent GABA test currents (data not shown). Alternating between GABA and 6a resulted in a progressive decline in the GABA test currents that finally led to a stable GABA current that was significantly lower, 68 ( 4% (n ) 4), than the initial GABA test current ( Figure 9A ). At this stage, application of MTSES -caused no further effect. In contrast, application of MTSES -to R 1 R66C 2 expressing oocytes untreated with 6a produced 62 ( 3% (n ) 4) inhibition of GABA currents. Furthermore, the GABA currents after either 6a or MTSES -application could be recovered by application of the reducing agent DTT (10 mM, 20 s) ( Figure 9A ). Theoretically, oxadiazole-2-thiones, such as 6a, can exist in two tautomeric forms, the thio-amide (thione) form and the imino-thiol form. IR, UV, and NMR spectra indicate that they do exist predominantly in their thione form. 50 However, the ability to form the thiol-tautomer enables the -. The same series of reagents are applied as in panel A, except that the MTSES nonsat was coapplied with 3.6 mM GABA. The GABA current elicited by the next GABA test pulse (middle trace) is significantly larger than the GABA current after the MTSES nonsat application in panel A, indicating that the presence of GABA significantly reduced the extent of reaction with the nonsaturating concentration of MTSES -. (C) 6a protects R1F64C 2 from modification by MTSES -. The same series of reagents are applied as in panel A, except that the MTSES nonsat was coapplied with 10 mM 6a. The GABA current elicited by the next GABA test pulse (middle trace) is significantly larger than the GABA current after the MTSESnonsat application in panel A, indicating that the presence of 6a significantly reduced the extent of reaction with the nonsaturating concentration of MTSES -. Currents during MTSES -application (V) with or without agonist are not shown. Duration of application of GABA EC 50 test pulses are indicated by black horizontal bars above the current traces.
oxadiazole-2-thione to form a disulfide bond. Consistent with the idea of the formation of a stable disulfide bond, repeated 10 s applications of 30 mM 5a, a 6a analogue with an oxygen in place of the potentially sulfhydryl reactive oxadiazolethione sulfur moiety, did not irreversible alter the subsequent GABA currents in R 1 R66C 2 expressing oocytes ( Figure 9B ).
To measure the reaction rate of 6a with R 1 R66C, we alternately applied 5.5 mM GABA and 6a to oocytes until the GABA currents no longer declined ( Figure 9A ). The decline in the R 1 R66C 2 GABA currents as a function of the cumulative 6a exposure time could be fit with a single exponential decay function. 6a second-order reaction rate with the engineered cysteine in R 1 R66C was 5 Figure 9A ,C). The second-order reaction rate constant was independent of the 6a concentration used (either 10 or 30 mM).
In our homology model based on the AChBP structure, the R 1 subunit residues R66 and T129 are in close proximity but on adjacent -strands. On the basis of protection with agonist and antagonist SCAM analysis predicts that R 1 T129 lines the binding pocket. 48 A 2 min application of 5 mM MTSES -reduced the subsequent currents elicited by GABA EC 50 test pulses in R 1 T129C 2 by 63 ( 5% (n ) 3). We tested whether 6a would react with R 1 T129C. Alternate application of EC 50 GABA and 30 mM 6a did not lead to a change in GABA EC 50 peak currents in R 1 T129C 2 , R 1 F64C 2 , or R 1 S68C 2 containing receptors, suggesting that the reaction of 6a with R 1 R66C is highly specific. It should be noted that the MTSES -reaction rate with R 1 R66C was at least 5-fold slower than with any of the other cysteine mutants used in this study (Table 6 ). It was orders of magnitude slower than the reaction rate with R 1 T129C. Thus, the lack of 6a reaction with the other cysteine mutants is not due to lower intrinsic reactivity of those positions.
Discussion
Structure-Activity Relationships of 1,3,4-Oxadiazol-2-ones. The 1,3,4-oxadiazol-2-one compound with the highest affinity as measured by inhibiting muscimol binding is the aminomethylderivative 5d, with IC 50 values of 1.4 µM and 1.1 µM against rat cortex and cerebellum, respectively. The homoderivative 5g with its 2-aminoethyl side chain displayed seven times higher IC 50 values. The conversion of the primary amine function of 5d to a secondary methylaminomethyl group in 5e caused a significant decrease in affinity, and the tertiary dimethylaminomethyl compound 9c showed negligible capacity to displace [ 3 H]muscimol. Thus, the affinity among the 5-aminomethyl- -either in the absence of agonist or in the presence of EC 90 GABA or 6a (10 or 30 mM). We infer that a reagent, GABA or 6a, protected a mutant from reaction with MTSES -if the extent of inhibition by MTSES -coapplied with either GABA or 6a is significantly less than the extent of inhibition by MTSES -applied alone. Conditions where the coapplication of GABA or 6a are significantly different than the effect of MTSES -application alone are indicated by * (* P < 0.014; *** P < 0.0001) by one way ANOVA and Fisher's PLSD. For R 1R66C 2, 30 µM MTSEA-biotin reduced the subsequent GABA test currents by 93%. Application of 30 µM MTSEA-biotin with 30 mM 6a reduced the subsequent GABA test currents by 83%. The limited supply of 6a precluded further experiments. -(V) had no effect, indicating that all accessible cysteine had reacted with 6a. Reduction by a 20 s application of 10 mM DTT (V) led to complete recovery of the GABA test current magnitude. Currents during application of 6a, MTSES -, and DTT are not shown. (B) Application of the oxygen analogue 5a (30 mM, 10 s) (V) to an oocyte expressing R 1R66C 2 did not decrease the subsequent GABA test currents. Currents during 5a application are not shown. (C) Reaction rate of 6a with R 1R66C 2. GABA test currents were normalized to the initial GABA test current, plotted as a function of cumulative duration of 6a application and fitted to a monoexponential decay function.
3H- [1, 3, 4] oxadiazol-2-ones decreases from the primary aminomethyl 5d over the secondary methylaminomethyl 5g to the tertiary dimethylaminomethyl 9c. We infer that the amino group is involved in interactions with the binding site because the cyclohexyl-9d and methyl-9e substituted oxadiazol-2-ones that lack an amino group do not show significant inhibition of muscimol binding.
An additional steric demand at the methylene group of the aminomethyl compound 5d that led to the 1-aminoethyl derivative 5f was not well tolerated, i.e., the methyl group in 5f led to a significant decrease in the ability to displace [ 3 H]muscimol. The 2-pyrrolidine compound 5c, which can be considered as a bridged aminomethyl derivative of 5d, showed an almost complete loss of affinity. In 5c, the inhibition reducing effects of a secondary amine function and a steric strain added to the methylene group are combined. Similarly, when the 2-aminoethyl side chain was incorporated into a 3-piperidyl ring as in 5b, the compound was inactive. However, the 4-piperidyl compound 5a was active although the IC 50 was increased by a factor of 4 when compared to the 2-aminoethyl compound 5g. Thus, the affinity appears to be sensitive to the position of the amino group because when it is at the 4 position in the piperidyl ring as in 5a, the IC 50 was 183 µM, but when located at the 3 position in 5b, the affinity was negligible. Furthermore, derivatives of the 4-piperidyl amino group leading to tertiary amines in the form of the N-benzyl-piperidine 9b or the N-methylpiperidine 9a showed weak activity in this assay. This is consistent with the loss of activity as the amino group transits from a primary to secondary to tertiary amino group.
Structure-Activity Relationships of 1,3,4-Oxadiazol-2-thiones. The 4-piperidyl derivative 6a showed an IC 50 comparable to the aminomethyl derivative 6d. This is in contrast to the oxadiazolones, where the aminomethyl derivative showed a 40 times lower IC 50 than the 4-piperidyl derivative. The aminoethyl derivative 6g showed the third highest degree of inhibition in the thione series. However, when the aminomethyl or aminoethyl was bridged in the thione series to obtain a 2-pyrrolidinyl 6c or 3-piperidinyl 6b compound, a significant amount of affinity was still retained. This is also different from the oxadiazolones, where the corresponding modifications were not tolerated. Another difference was found when comparing the primary, secondary, and tertiary aminomethyl compounds. Here the primary aminomethyl 6d had a higher affinity than the dimethylaminomethyl compound 10c, which in turn had a higher affinity than the methylaminomethyl compound 6e. This decline in affinity seems to be correlated to the basicity. We infer that the amine-N interacts with the protein. Other side chains that resulted in a weak affinity are the compounds with the 4-(N-methyl-piperidinyl) 10a and the 4-(N-benzyl-piperidinyl) 10b moiety. Again, the cyclohexyl-and methyl substituted oxadiazol-2-thiones 10d and 10e did not show a significant inhibition of muscimol binding.
Structure-Activity Relationships of Modifications to the 1,3,4-Oxadiazol-2-one Ring Itself. As mentioned above, substituting the 2-one oxygen with sulfur did not have a uniform effect. Depending on the amine-side chain in position 5 of the heterocycle, the sulfur bearing compound exhibited lower (4-piperidinyl, 6a < 5a; 3-piperidinyl, 6b < 5b; 2-pyrrolidinyl, 6c < 5c) or higher IC 50 values (aminomethyl, 6d > 5d; 2-aminoethyl, 6g > 5g; methylaminomethyl, 6e > 5e) than their oxygen bearing counterparts. For other side chains, there was no difference in affinity detected between -thione and -one (Nmethyl-piperidine, 9a ) 10a; N-benzyl-piperidine, 9b ) 10b) . The 4-piperidinyl series 5a, 6a, 19 showed that the hydrogens of the oxadiazol-2-one/oxadiazol-2-thione 3-nitrogen or of the tautomeric oxadiazol-2-ol/oxadiazol-2-thiol 2-alcohol/2 thioalcohol oxygen/sulfur are unlikely to be directly involved in hydrogen-bonding nor, in their deprotonated form, in ion-ion or ion-π interactions because the 2-methyl-1,3,4-oxadiazole showed intermediate affinity. Moreover, we infer that the heteroatoms in the 1,3,4-oxadiazol ring act as hydrogen-bond acceptors when interacting with amino acids in the binding site. However, the drop in affinity from 6a over 19 to 5a followed the decrease in volume of the 2-substituent of the 1,3,4-oxadiazol (sulfur > CH 3 > oxygen). The compound with the smallest substituent (hydrogen) at position 2 of the 1,3,4-oxadiazol 11 showed a complete loss of affinity opposite to the derivatives with an oxygen 9b or sulfur 10b, again indicating that some bulk at the 2-position is necessary.
The 1,2,4-triazoles explore the effect of substituting the oxygen at position 1 of the 1,3,4-oxadiazol-ones/thiones with a benzyl substituted nitrogen. This exchange was not tolerated at all in the aminomethyl compound: the triazole 16d completely lost its affinity in contrast to the 1,3,4-oxadiazol-2-one, whereas the 4-piperidinyl triazole 16a showed a reduced but still significant displacement of [
3 H]muscimol. The difference in tolerance of bulk at this position of the heterocyclic half of the compounds might indicate that the longer piperidine derivatives share the binding partners for the side chain amino-N with the shorter ligands but bridge to different amino acids of the binding site with the heterocyclic portion of the molecule. This difference in coordination might account for the difference in tolerance for bulky substituents.
Comparison with Previous 4-PIOL Derivatives. Frølund and colleagues have reported on the synthesis and evaluation of 4-PIOL derivatives as GABA partial agonists or antagonists. They mainly investigated the influence of substituents at position 4 of the 3-isoxazolol ring. 39, 54 In these studies, small aliphatic and also bulky aromatic substituents were tolerated. 4-PIOL derivatives in these investigations had a K i between 0.049 and 10 µM as compared to 4-PIOL with 9.1 µM and our best derivatives with an IC 50 between 1 and 183 µM. Methyl or ethyl substitution of 4-PIOL lead to compounds that retained some agonistic activity with the binding affinity as determined by [ 3 H]muscimol binding assays being retained as well, whereas the bulky substituents did not show agonistic activity, but their affinity was increased in the binding assays. In the context of the 1,3,4-oxadiazol-2-ol moiety used in the present study, substitution of the oxygen at position 1 with a benzyl substituted nitrogen did not improve affinity as 16a had a somewhat lower affinity than 5a. We infer that the large cavity that has been suggested to accommodate the aromatic residues of the 4-subsituted 4-PIOL derivatives is not available for compounds of our series, possibly because the 1,3,4-triazol-2-ol derivatives are not arranged in a way that would align the aromatic moiety with the hydrophobic pocket. It is likely that the occupancy of this cavity by the aromatic substituted 4-PIOL derivatives prevents the binding site closure that has been proposed to be an early step in the conformational change linking ligand binding to channel gating.
It has been observed previously that the exchange of an oxygen in the small carboxyl group bioisosteric ring by a sulfur can have different effects: the sulfur analogue of 4-PIOL has a higher affinity than 4-PIOL, whereas the sulfur analogue of THIP has a lower affinity than the oxygen containing counterpart. 40 54 r-Subunit Specificity. The electrophysiological characterization of the most active compounds was divided in investigating the agonistic potency of individual compounds and determining their modulating effect on GABA-induced currents. The agonistic profiling yielded 5d as the most active compound. This compound had an EC 50 comparable to the GABA EC 50 at all R 1-6 3 γ 2 subunit combinations, ranging from 30 µM for R 6 to 1 mM for R 3 -containing receptors. In the GABA current modulating assay, 5d showed potentiating effects at all subunit combinations reflecting its pure agonistic character. We assume that the small 5d compound can be accommodated in all binding sites irrespective of the specific R subunit, where its orientation and size allow complete agonist-induced contraction of the binding site and subsequent gating in a manner comparable to the GABA induced effect. Increasing the spacer that bridges the basic amino function from the oxadiazolol moiety from a methylene group in 5d to a piperidine ring in 5a converts the compound from an unselective agonist into an antagonist at R 1 , R 4 , and R 6 containing receptors and a weak partial agonist at R 2 , R 3 and R 5 containing receptors. The intrinsic activity is highest at R 5 containing receptors. The thio derivative of 5a, 6a, showed a comparable profile, with the exception that at R 2 containing receptors it is potentiating GABA currents at low concentrations while it is inhibitory at higher concentrations. The methyl derivative 19 was only agonistic at R 6 receptors, while it showed slight potentiating effects at high concentrations at R 2 , R 4 , R 5 , and R 6 containing receptors.
6a Binds in the GABA Binding Site. Numerous drugs modulate and directly activate GABA A receptors often by binding to sites other than the GABA binding sites. On the basis of several lines of evidence, we conclude that 6a binds within the GABA binding pocket. First, 6a protected R 1 F64C and R 1 S68C from modification by MTSES - (Figures 7 and 8 ). These residues are located in the GABA binding site in a homology model based on the AChBP structure. 49, [56] [57] [58] Czajkowski and co-workers previously showed that GABA protected the cysteine at R 1 F64C from modification by MTSES -but pentobarbital did not. Pentobarbital activates the receptor by binding at a site in the transmembrane domain. Thus, the lack of protection by pentobarbital argues that the protection induced by GABA is due to local steric effects of GABA and not due to conformational changes associated with gating. 46 ,47 Thus, we conclude that 6a protected R 1 F64C by its presence in the GABA binding site and not by conformational changes induced by 6a binding. Second, 6a specifically and covalently modified the neighboring cysteine-substitution mutant, R 1 R66C, inhibiting the subsequent GABA currents. This inhibition did not occur with 5a, which has an oxygen in place of the thiol-reactive sulfur in 6a. Furthermore, following inhibition of R 1 R66C by reaction with 6a subsequent application of MTSES -had no effect, whereas, without 6a pretreatment, application of MTSES -would have inhibited the GABA-induced currents. Thus, MTSES -had no effect when it was applied after 6a because MTSES -cannot react with disulfide linked sulfurs. In contrast, the inhibition induced by 6a reaction was reversed by DTT application, indicating that 6a formed a mixed disulfide bond with the cysteine thiol. Taken together, we infer that 6a binds in the GABA binding site.
The ability of 6a to protect R 1 S68C from modification by MTSES -provides insight into the conformational changes induced by 6a binding (Figure 8 ). Both GABA and pentobarbital protected this cysteine mutant from MTSES -modification. Czajkowski and co-workers concluded that in the activated state conformation, access to this residue was reduced due to a conformational change of the binding site rather than by the presence of GABA in the binding site. 59 We infer that in the region of R 1 S68, 6a produces a similar conformational change to that induced by GABA and pentobarbital when it activates the receptor. This suggests that 6a induces a conformational change in the receptor similar to that induced by GABA binding.
Further, the disulfide bond formation between 6a and the introduced cysteine at the R 1 R66 position provides insight into the orientation of 6a in the GABA binding site. The reaction between 6a and R 1 R66C appears to be specific because 6a did not react at a measurable rate with the cysteine substituted for the neighboring residues on the same strand, R 1 F64 or R 1 S68, nor did it react with a cysteine at R 1 T129, the residue predicted to lie in closest proximity on the adjacent strand. If all other factors were similar, the ratio of the reaction rates of 6a with the four cysteine mutants should be similar to the ratio of the reaction rates for the MTS reagents with these mutants. The MTS reagents reacted faster with R 1 F64C and R 1 S68C than with R 1 R66C (Table 6 ). Thus, it is surprising that 6a only reacted at a measurable rate with R 1 R66C. Because 6a is much less reactive than the MTS reagents, the reason why this compound only reacts at this position must be attributed to a highly selective interaction of the 6a sulfur with the R 1 R66C sulfur. Therefore, we infer that the favorable orientation of 6a in the binding site brings the 6a sulfur into close proximity with the R 1 R66 position, leading to the highly specific reaction. This establishes one point of contact between 6a and the complementary side of the binding site.
We assume that 6a bridges the principle and complementary sides of the binding site in a manner similar to GABA. We generated a model of the GABA A receptor 2 -R 1 interface based on the AChBP crystal structure with nicotine bound (Figure 10 ). 6a can fit into the binding site with its basic nitrogen superposed on the position of nicotine's basic pyridine nitrogen in the principle side of the binding site and with the 6a sulfur in close proximity to the introduced R 1 66C sulfur on the complementary side of the binding site ( Figure 10B ). The close proximity of the sulfurs may explain the high collision probability and consequently the reactivity necessary to form the disulfide bond between 6a and the engineered cysteine at position R 1 R66. This orientation in the binding site may explain why it is a weak agonist. In the AChBP crystal structure on the complementary side of the binding site, nicotine forms hydrogen bonds with backbone carbonyls and amides on the strand containing the residue that aligns with R 1 T129 ( Figure 10C ). This strand is adjacent to the R 1 R66-containing strand. 6a is larger than GABA: the distance between the two potential H-bonding sites, i.e., the protonated positively charged nitrogen and the most distant high electron dense heteroatom O (GABA) and S (6a) (Figures 11 and 10 ) being 6.1 and 7.6 Å, respectively. Thus, GABA might only span the distance between the -subunit principle site residues, where the positively charged N is coordinated and the R 1 T129 -strand of loop E ( Figure  10A ). In contrast, the larger 6a extends to the more distant strand containing residue R 1 R66 ( Figure 10B ). Activation of the Cys-loop receptors may involve a contraction of the two halves of the binding site. 59 Because 6a bridges to a different part of the complementary side of the binding site its ability to pull the two halves of the binding site together may be reduced compared to GABA, resulting in 6a being a partial agonist. The idea that 6a is a partial agonist because it is less effective at closing the binding site is consistent with the conceptual model of partial agonism derived from structural studies of the ionotropic glutamate receptors. 60 6a should not cover the R 1 loop connecting L117 and L127 that harbors the four amino acids (ITED in R 1 ) recently identified as R variant specific transducing elements rather than binding site elements. 4 A trap-like motion of this loop, to an extent specified by these four amino acids in a given R isoform, could further explain the differences in GABA sensitivities between the GABA A receptor subtypes.
Conclusions
We synthesized a series of derivatives of 4-PIOL, a compound previously shown to be a weak GABA A partial agonist. We started by replacing the 3-isoxazolol moiety in 4-PIOL with a 1,3,5-oxadiazol-2-ol moiety to yield 5a. For the first time, we describe GABA A receptor ligands with a 1,3,5-oxadiazol-2-ol as a carboxylic acid bioisosteric group. Compound 5a was modified at different positions to investigate structure-activity relationships: the piperidine moiety was exchanged and modified, the substituent at the 2 position of the 1,3,5-oxadiazol-2-ol was varied, and the 1,3,5-oxadiazol-2-ol was exchanged by 1,2,4-triazol-5-ol. . CPK color scheme used: carbon, white; nitrogen, blue; oxygen, red; sulfur, yellow. (C) Electrostatic potential mapped onto the van der Waals surface of GABA (top) and 6a (bottom) with stick representation of molecules. Red indicates negative electrostatic potential and blue is positive potential. Image generated using Spartan. Note the similarity of the overall electrostatic potential, especially the distance between the positively charged nitrogen in GABA or 6a to the negative carboxylate (GABA) or the oxadiazolthione moiety (6a).
The most active piperidine derivatives 5a and 6a were weak partial agonists that differentiated weakly between different R subunit containing receptors, whereas the small aminomethyl 5d showed a profile of a pure agonist that is very similar to GABA.
The described structure-activity relationships extend the currently available information for ligands of the agonist binding site of the GABA A receptor. Frølund et al. have shown previously how to convert 4-PIOL into pure antagonistic compounds, while we now show how 4-PIOL can be modified to either obtain a pure or partial agonists with weak R subtype preferring profiles.
In addition, this study demonstrates that 6a binds in the GABA binding site and that 6a is oriented in the binding site such that its interaction with the complementary portion of the binding site is displaced from the interaction site of nicotine and carbamylcholine in the AChBP structure. The later finding may explain why 6a is a partial agonist. Further investigations are necessary to determine if the two GABA binding sites are the only sites involved in the activity of this compound. These results coupled with GABA binding site homology models based on the AChBP structure may provide a foundation for rational design of GABA A receptor subtype-specific agonists with higher efficacy and specificity.
Experimental Section
Chemistry. Procedures and spectroscopic data for nontarget compounds can be found in the Supporting Information.
General Procedures for the Removal of the Boc-group: Procedure F (Compounds 5a,c,e,f,g, 6c,d,e,f,g, 16a,d, 17a,  19) . The Boc-protected amine (1 equiv) was dissolved in a minimum amount of methanol and cooled in an ice-bath in a nitrogen atmosphere. After adding ethanolic HCl 2.3 N (4.5 equiv), the mixture was allowed to reach room temperature and stirred overnight. Products were isolated by filtration in a nitrogen atmosphere; in some cases, a precipitate was only formed after adding ethyl acetate (50-98%).
Procedure G (Compounds 5b,d, 6a,b, 19) . The Boc-protected amine was dissolved in ethyl acetate and cooled to -20°C in a nitrogen atmosphere. Gaseous HCl was bubbled through the mixture for 5 min. The reaction was allowed to come to room temperature and stirred until a precipitate was formed. Products were isolated by filtration in a nitrogen atmosphere or after removing the solvent and recrystallization in ethanol (56-88%).
5-Piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one Hydrochloride (5a).
Starting from 3a, the compound was synthesized as described in procedure F: white crystals (98%); mp ) 314°C. 
5-Piperidin-3-yl-3H-[1,3,4]oxadiazol-2-one Hydrochloride (5b).
Starting from 3b, the compound was synthesized as described in procedure G. The solvent was removed under reduced pressure and the residue recrystallized from ethanol: white crystals (66%); mp ) 207°C. 1 
5-Piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione Hydrochloride (6a).
Starting from 4a, the compound was synthesized as described in procedure G (74%). The compound was also synthesized following procedure F. In this case, 1 / 3 of methanol cocrystallized with 6a, which could be removed by solving the crystals in water, removing some of the solvent under vacuum at 20°C and freeze-drying the resulting solution (91%): white crystals; mp ) 232°C. 
5-Piperidin-3-yl-3H-[1,3,4]oxadiazol-2-thione Hydrochloride (6b).
Starting from 4b, the compound was synthesized as described in procedure G, with the exception that 10% of the solvent were ethanol. The solvent was removed under reduced pressure and the residue recrystallized in ethanol: slightly green crystals (58%); mp ) 219°C. 
5-Aminomethyl-3H-[1,3,4]oxadiazol-2-thione Hydrochloride (6d).
Starting from 4d, the compound was synthesized as described in procedure F: beige crystals (71%); mp ) 184°C. d 6 ) δ 4.21 (s, 2H, CH 2 ), 8.93 (s, 3H, NH 3 ), 14.83 (s, 1H, NH) . 13 -3H-[1,3,4]oxadiazol-2-thione Hydrochloride (6e) . Starting from 4e, the compound was synthesized as described in procedure F: white crystals (81%); mp ) 158°C. (Compounds 9a-c) . The tertiary amine (2 equiv) was dissolved in CH 2 Cl 2 and cooled to 0°C under a nitrogen atmosphere. After adding a solution of carbonic acid bis(trichloromethyl) carbonate (1 equiv) in CH 2 Cl 2 dropwise, the mixture was refluxed. The reaction mixture was evaporated to dryness and the residue recrystallized or chromatographed (20-55%). Methyl-piperidin-4-yl)-3H-[1,3,4 ]oxadiazol-2-one (9a). Starting from 8a, the compound was synthesized as described in procedure H and recrystallized from methanol: white crystals (55%); mp ) 281°C. 1 
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5-(1-Benzyl-piperidin-4-yl)-3H-[1,3,4]oxadiazol-2-one Hydrochloride (9b).
Starting from 8b, the compound was synthesized as described in procedure H and recrystallized from methanol: white crystals (55%); mp ) 253°C. The NMR-and MS-data agreed with literature. 61 Anal. (C 14 H 17 N 3 O 2 · HCl) C, H, N. -3H-[1,3,4]oxadiazol-2-one (9c) . Starting from 8c, the compound was synthesized as described in procedure H. The mixture was poured onto water and extracted with ethyl acetate at pH 7. The combined organic extracts were dried (Na 2 SO 4 ), the solvent was removed under vacuo, and the residue chromatographed with ethyl acetate: white crystals (20%); mp ) 103°C; R f (ethyl acetate): 0.09. 
5-Dimethylaminomethyl
5-Methyl-3H-[1,3,4]oxadiazole-2-one (9e).
Starting from 8e, compound 9e was prepared according to procedure H and recrystallized from CH 2 Cl 2 and n-hexane: white crystals (67%); mp ) 112°C . 63 13 C NMR-data agreed with literature. 
5-(1-Methyl-piperidin-4-yl)-3H-[1,3,4]oxadiazole-2-thione (10a).
A mixture of 8a (1 equiv), pyridine (1.6 mL/equiv), and CS 2 (0.2 mL/equiv) was treated at 80-90°C until the evolution of H 2 S had stopped. After removing the solvent under reduced pressure, the residue was recrystallized in ethanol and subsequently in methanol. The compound was chromatographed and again recrystallized from methanol: beige crystals (17%); mp ) 248°C; R f (methanol): 0.5. 1 H NMR (DMSO-d 6 ) δ 1.71-1.84 (m, 2H, 2CH), 2.00-2.10 (m,  2H, 2CH), 2.61 (s, 3H, CH 3 ), 2.75-2.95 (m, 3H, 3CH), 3.18-3.27  (m, 2H, 2CH ). 13 N 3 OS) C, H, N, S.  5-(1-Benzyl-piperidin-4-yl)-3H-[1,3,4]oxadiazole-2-thione (10b) . Compound was synthesized according to the synthesis described for compound 10a starting from 8b: slightly beige crystals (34%); mp ) 220°C; R f (chloroform/methanol ) 4/1): 0.4. The NMRand MS-data agreed with literature. 61 Anal. (C 14 H 17 N 3 OS) C, H, N, S.
5-Dimethylaminomethyl-3H-[1,3,4]oxadiazole-2-thione (10c).
Starting from 8c, the compound was synthesized as described in procedure E. The mixture was poured onto water and extracted with ethyl acetate at pH 7. The combined organic extracts were dried (Na 2 SO 4 ), the solvent was removed under vacuo, and the residue chromatographed: beige crystals (5%); mp ) 119°C; R f (ethyl acetate): 0.08. 1 (Compounds 11, 18) . The hydrazide was refluxed for two hours in excess triethoxyalkane. Afterward, alcohol, which is formed during the reaction, was removed by distillation. The residue was refluxed for 5 h. After cooling to RT, the mixture was treated with water, saturated with K 2 CO 3 , and extracted several times with ethyl acetate. The combined organic extracts were dried (Na 2 SO 4 ), evaporated and chromatographed (62-66%).
1-Benzyl-4-[1,3,4]oxadiazol-2-yl-piperidine (11).
Starting from 8b and triethoxyethane, the compound was prepared according to procedure I and chromatographed starting with petroleum ether/ ethyl acetate ) 1/1 and switching to methanol/ethyl acetate ) 1/1: white slightly beige crystals (62%); mp ) 61°C; R f (ethyl acetate/ petroleum ether ) 1/1): 0.1; R f (methanol/ethyl acetate ) 1/1): 0. 
5-Aminomethyl-4-benzyl-2,4-dihydro-[1,2,4]triazol-3-one (16d).
Starting from 12d, compound 16a was synthesized as described in procedure L; because no precipitate was formed, the mixture was extracted with several portions of ethyl acetate. The combined organic extracts were dried (Na 2 SO 4 ) and the solvent evaporated under vacuo until the crystallization started: white crystals (44%); mp ) 150°C. 1 for 20 min. The washing step was repeated four times before the membranes were frozen at -20°C. After slow thawing, the washing steps were repeated another two times and frozen again until use. Before each experiment, the membranes were recentrifuged and diluted to the desired protein concentration. Resuspended cell membranes (50-200 µg protein per tube) were incubated in a final volume of 0.5 mL of 50 mM Tris/citrate buffer, pH 7.3, for [ 3 H]muscimol binding (6 nM) with and without the novel compounds in the concentration range given in the text. Nonspecific binding was determined in the presence of 100 µM GABA. After 60 min on ice, the assay mixtures were rapidly diluted to 5 mL with ice-cold 10 mM Tris/HCl, pH 7.4, filtered through glass fiber filters (no. 52, Schleicher & Schuell, Dassel, Germany) and washed once with 5 mL 10 mM Tris/HCl, pH 7.4. Filters were immersed in 4 mL of Zinsser AquaSolv (Munich, Germany) scintillation fluid, and the radioactivity determined in a Beckman liquid scintillation counter using external standardization. Statistical calculations were performed using the Graph Pad Prism program (GraphPad Software, San Diego, CA.) with and without the novel compounds.
Cell Culturing and Cell Transfection. For electrophysiological recording, HEK-293 cells were passaged and replated on 12-mm glass coverslips located in 9.6-cm plastic dishes filled with 10 mL of Minimum Essential Medium (MEM, Gibco) supplemented with 158 mg/L sodium bicarbonate, 2 mM glutamine (Gibco), 100 U/mL penicillin-streptomycin (Gibco), and 10% fetal calf serum (Gibco).
Cultures were maintained at 37°C in a humidified 95% O 2 /5% CO 2 atmosphere for 2-3 days.
Transfection with recombinant rat GABA A receptors were carried out as described in detail. 66, 67 Briefly, HEK 293 cells were transfected using the calcium phosphate precipitation method with rat GABA A receptor cDNAs in eukaryotic expression vectors 68 for the R, , and γ subunits. For optimal receptor expression, final concentrations (µg vector DNA per 9.6 cm tissue culture plate) were: R 1 , 2; R 2 4.8; R 3 , 1.2; R 4 10; R 5 , 0.8; R 6 , 2; 3 , 0.4; and γ 2 S, 0.3. The γ 2 S variant is abbreviated γ 2 in the remainder of the text. To identify transfected cells, all subunit combinations were cotransfected with 1 µg per plate of pNI-EGFP.
HEK293 Electrophysiology. Two days after transfection, single coverslips containing HEK 293 cells were placed in a recording chamber mounted on the movable stage of a fluorescence microscope (Olympus IX70) and perfused with a defined saline solution containing (in mM): 130 NaCl, 5.4 KCl, 2 CaCl 2 , 2 MgSO 4 , 10 glucose, 5 sucrose, and 10 HEPES (free acid), pH adjusted to 7.35 with NaOH. Transfected cells were identified by their green fluorescence due to the expression of the pNI-EGFP vector. Ligandmediated membrane currents from these cells were studied using the whole-cell patch-clamp recording technique. 69 Patch pipettes were pulled from hard borosilicate capillary glass (0.5 mm i.d., 1.5 mm o.d., Vitrex, Science Products GmbH, Hofheim, Germany) using a horizontal puller (Sutter Instruments, CA, model P-97) in a multistage process. The pipettes had an initial resistance of 2-4 MΩ when filled with a solution containing (in mM): 90 KCl, 50 KOH, 2 CaCl 2 , 2 MgCl 2 , 10 EGTA, 3.1 ATP (dipotassium salt), 0.4 GTP (trisodium salt), and 10 HEPES (free acid), pH 7.35.
The junction potential between the pipet and the external solution was less than 2.3 mV and therefore was neglected. Seal resistances >1 GΩ were routinely obtained by applying gentle suction to the pipettes. Membrane rupture was monitored electrically as an increase in capacitance. Pipette capacitance, membrane capacitance, and series resistance were electronically compensated to minimize capacitive transients. A series resistance compensation of >60% was regularly used.
To analyze modulations of the GABA-induced currents, the approximate receptor subtype specific GABA EC 20 and increasing drug concentrations were applied to the cells using a fast perfusion stepper system (SF-77B, Perfusion Fast Step, Warner Instruments, Inc., Hamden, CT). In the case of 5a and 6a, the following concentrations were coapplied (in µM): 0.1, 1, 10, 100, 1000; for 19 and 5d, the concentration range used was (in µM): 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000. Additionally, the intrinsic activity of all compounds was tested by applying them alone to the cells in concentrations of 1, 10, 100, and 1000 µM.
Responses of cells were recorded by patch-clamp amplifier (EPC-8, HEKA-Electronic, Lambrecht, Germany) in conjunction with a standard personal computer and the pClamp 8.1 software package (Axon Instruments, Foster City, CA). The standard holding-potential for the cells was -40 mV. Whole cell currents were low-pass filtered by a eight-pole Bessel filter at 5 or 3 kHz before being digitized by a Digidata 1322A interface (Axon Instruments, Foster City, CA) and recorded by the computer at a sampling rate of at least 5 kHz.
Mutagenesis and Oocyte Expression. The rat GABA A receptor R 1 and 2 subunit DNA constructs in the pGH19 vector (R 1 wildtype (wt), R 1 F64C, R 1 R66C, R 1 S68C, R 1 T129C, 2 wt) were obtainedfromDr.CynthiaCzajkowski,UniversityofWisconsinsMadison. Their identity was verified by restriction digestion and DNA sequencing. Plasmids were linearized with NheI prior to in vitro mRNA transcription with T7 RNA polymerase (Amplicap T7 High Yield Message MakerTM, Epicenter Technologies, Madison, WI). mRNA was dissolved in diethylpyrocarbamate-treated water and stored at -80°C. Female Xenopus laeVis were purchased from Nasco Science (Fort Atkinson, WI). Stage V-VI oocytes were defolliculated with a 75 min treatment with 2 mg/mL type 1A collagenase (Sigma Chemical Co., St. Louis, MO) in OR2 (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES; pH adjusted to 7.5 with NaOH). Oocytes were washed thoroughly in OR2 and kept in SOS medium (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 5 mM HEPES, pH 7.5) supplemented with 1% antibiotic-antimycotic (100×) liquid (10000 IU/mL penicillin, 10000 µg/mL streptomycin, and 25 µg/mL of amphotericin B; Invitrogen, Carlsbad, CA) and 5% horse serum (Sigma). Oocytes were injected 24 h after isolation with 50 nL (10 ng) of a 1:1 mixture of rat R 1 : 2 subunit mRNA and were kept in horse serum medium for 2-10 days at 17°C. Mutant subunit mRNA was substituted for wt R 1 subunit where necessary.
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Two-Electrode Voltage Clamp Recording. The electrophysiological recordings were conducted at room temperature in a ∼250 µL chamber continuously perfused at a rate of 5-6 mL/min with Ca 2+ -free frog Ringer buffer (CFFR; 115 mM NaCl, 2.5 mM KCl, 1.8 mM MgCl 2 , 10 mM HEPES pH 7.5 with NaOH) using equipment and procedures described previously. 52 Currents were recorded from individual oocytes using two-electrode voltage-clamp at a holding potential of -60 mV. The ground electrode was connected to the bath via a 3 M KCl/Agar bridge. Glass microelectrodes had a resistance of <2 MΩ when filled with 3 M KCl. Data were acquired and analyzed using a TEV-200 amplifier (Dagan Instruments, Minneapolis, MN), a Digidata 1200 or Digidata 1322A data interface (Axon Instruments, Union City, CA), and pClamp 7 or pClamp 8 software (Axon Instruments). Currents (I GABA ) were elicited by applications of GABA separated by at least 5 min of CFFR wash to allow complete recovery from desensitization. Currents were judged to be stable if the variation between consecutive GABA pulses was <10%.
Reagents. The sulfhydryl-reactive methanethiosulfonate (MTS) reagents used in these experiments were 2-sulfonatoethyl methanethiosulfonate (MTSES -) and 2-((biotinoyl)amino)ethyl methanethiosulfonate (MTSEA-biotin) (Biotium, Inc., Hayward, CA). MTS-reagents react with cysteine (Cys) and covalently couple a 2-sulfonatoethylsulfide (MTSES -) or a 2-((biotinoyl)amino)ethylsulfide moiety (MTSEA-biotin) onto protein sulfhydryls. A 100 mM stock solution of MTSES -in water or MTSEA-biotin in DMSO was prepared daily and kept on ice. The working solutions were obtained by diluting the 100 mM stock solution in CFFR immediately before use. GABA (Sigma) was prepared as a 100 mM stock solution in water. Dithiothreitol (DTT) (Sigma) was dissolved in water to obtain a 1 M stock solution and diluted into CFFR before each experiment.
GABA and 6a Concentration-Response Relationships. The GABA EC 50 s for wt or mutant R 1 2 receptors were determined using the two-electrode voltage clamp technique on Xenopus laeVis oocytes. To determine the GABA concentration-response relationship, progressively increasing GABA concentrations were applied to oocytes expressing wt or mutant receptors. The currents were normalized to the maximal GABA-induced current (I max ). The GABA concentration-response relationship was determined for each mutant by least-squares minimization (GraphPad Prism 3.0, GraphPad Software Inc., San Diego, CA; SigmaPlot 2000, SPSS Inc., Chicago, IL) of the currents to a logistic equation of the form:
where n is the Hill coefficient and EC 50 is the GABA concentration that gives rise to 50% of the maximal current. Parameters from several oocytes were averaged to obtain the mean EC 50 and Hill coefficient. Data are presented as mean ( SEM except where the number of experiments performed is two, in which case average errors are given.
For R 1 2 wt, R 1 F64C 2 , and R 1 S68C 2 receptors, we also performed concentration-response experiments with 6a, which directly activates at high concentrations, to measure the EC 50 for this compound. For 6a dose-response curves, only two trials were performed for some mutants due to the limited supply of 6a.
Determination of 6a IC 50 . The IC 50 for 6a was determined by coapplying progressively increasing test concentrations of 6a with a constant GABA concentration. For each receptor, the GABA EC 20 concentration was used. We used a low GABA concentration for our inhibition experiments because of the limited availability of 6a. Inhibition was calculated as I GABA+6a /I GABA . Data were fit to the following equation:
where IC 50 is the concentration of 6a that blocks half of I GABA ; [6a] is the concentration of 6a, and n is the Hill coefficient.
Picrotoxinin Blockade of 6a-Induced Currents. We applied several 6a (10 mM) test-pulses to R 1 2 receptors and recorded the induced currents. Following wash-out, we applied the open-channel blocker picrotoxinin (100 µM), immediately followed by a coapplication of 6a and picrotoxinin (10 mM and 100 µM) and recorded the current trace.
Determination of MTS Reagent Reaction Rates. The MTS reagent was applied repeatedly in the extracellular bath for brief periods. Before and between each application of MTS reagent, the GABA-induced current was determined. For each mutant, the MTSreagent concentration to be used was chosen based on preliminary experiments so that the reaction would proceed to completion in 1-2 min of cumulative MTS-reagent application time (MTSES -concentrations used: R 1 F64C, 10 µM; R 1 R66C, 250 and 500 µM; R 1 S68C, 150 µM; R 1 T129C, 10 nM; MTSEA-biotin concentration used: R 1 R66C, 10 or 40 µM; R 1 T129C, 10 nM). The peak GABA test currents were normalized to the initial GABA current, plotted as a function of the cumulative MTS-reagent application time and fitted with a monoexponential function of the form, I ) ( I 0 -I ∞ ) e -tτ′ + I ∞ where I 0 is the value of the GABA-induced current amplitude before modification, I ∞ is the current amplitude at the end of the reaction, t is the cumulative MTS-reagent application time, and τ′ is the pseudo-first-order rate constant (s -1 ). The second-order rate constants, τ, were calculated by dividing the pseudo-first-order time constants τ′ by the MTS-reagent concentration. The second-order rate constants were independent of the MTS-reagent concentrations used. MTS-reagent reaction rates were determined for R 1 F64C, R 1 R66C, as well as R 1 S68C containing R 1 2 GABA A receptors. Data are presented as mean ( SEM These rates were used to calculate the concentration and time of application of MTS-reagent that produces submaximal, nonsaturating inhibition.
Determination of 6a Reaction Rates in r 1 R66C 2 Receptors. 6a was applied repeatedly in the extracellular bath for brief periods. Before and between each 6a application, the GABA-induced current was determined. The 6a reaction rate with the engineered R 1 R66C was determined as described above for MTS-reagents. Once the alternating 6a and GABA applications produced a reduced but stable GABA current, we applied a saturating amount of MTSES -(10 mM, 12 s) in order to determine whether all of the engineered cysteines had reacted with 6a. To demonstrate that the 6a inhibition of R 1 R66C was due to formation of a disulfide bond between 6a and the engineered cysteine thiol, we applied DTT (10 mM, 20 s) and measured the GABA current again.
Protection Assay with 6a or GABA in Mutant r 1 2 Receptors. To demonstrate that 6a or GABA bound in close proximity to an engineered cysteine, we assayed the ability of these agonists to protect the cysteine from reaction with an MTS reagent. To maximize our ability to detect protection, we used concentrations of MTS reagents and durations of application that caused large but submaximal inhibition of the subsequent GABA test currents. For a 12 s application, the MTSES -concentrations used were: R 1 F64C, 10 µM; R 1 R66C, 2 mM; R 1 S68C, 450 µM; and MTSEA-biotin concentration: R 1 R66C, 30 µM. To detect protection for a given mutant, an initial GABA test current was determined. We coapplied a concentration-duration of MTS-reagent that produced submaximal inhibition together with 6a (10 or 30 mM) or GABA EC 90 concentrations. After washout, the remaining GABA-induced current was determined. To determine the percent inhibition caused by the MTS + 6a or GABA coapplication, it was important to determine the maximum extent of inhibition for each oocyte. This was determined by a subsequent application of a saturating amount of MTS reagent (MTSES -concentration: R 1 F64C, 20 µM, 50 s; R 1 R66C, 10 mM, 12 s; R 1 S68C, 5 mM, 12 s; MTSEA-biotin concentration: R 1 R66C, 300 µM, 12 s) followed by a determination of the current induced by a subsequent GABA-test pulse. If the extent of inhibition resulting from coapplication of the MTS reagent with 6a or GABA was less than the extent of inhibition when just the MTS reagent was applied, then we inferred that 6a and/or GABA had protected the cysteine from modification by the MTS reagent. The amount of reaction was calculated using the equation:
%reduction ) ( I 0 -I ) ⁄ ( I 0 -I ∞ ) × 100
where I 0 is the value of the GABA-induced current amplitude before modification, I is the current amplitude after application of the concentration and duration of MTS-reagent that produced submaximal inhibition with or without ligand (GABA or 6a), and I ∞ is the current amplitude at the end of the reaction after maximal inhibition. Note that the MTS-reagent rates of reaction were done by applying the reagents via a continuous perfusion system. In the protection assay, we used a syringe application system that allowed us to use small volumes because of the limited availability of 6a. Homology Modeling. The extracellular domains of rat GABA A receptor R 1 and 2 subunits were modeled on the basis of the 2.2 Å crystal structure of the homologous homopentameric acetylcholinebinding protein (AChBP) with nicotine bound (PDB 1UW6). Using Deep View/Swiss Pdb-Viewer v3.7, 71 we aligned the R 1 and 2 subunit sequences with the AChBP A and E chain, respectively. 57 The AChBP structure aligned with the raw sequence was submitted as a modeling request in Swiss model. The resulting homology modeled R 1 2 structure was subsequently subjected to energy minimization and later rendered with POV-Ray v3.6 (http:// www.povray.org/). 72 
